• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

作者信息

Lucore C L, Sobel B E

机构信息

Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.

出版信息

Circulation. 1988 Mar;77(3):660-9. doi: 10.1161/01.cir.77.3.660.

DOI:10.1161/01.cir.77.3.660
PMID:2449299
Abstract

To delineate interactions of infused tissue-type plasminogen activator (t-PA) with inhibitors in plasma and their impact on fibrinolytic activity, serial plasma samples from patients with acute myocardial infarction and from normal rabbits given infusions of t-PA were assayed for t-PA antigen, activity of "fast acting" plasminogen activator inhibitor (PAI-1), and the presence and nature of t-PA-inhibitor complexes. In patients, endogenous t-PA circulated predominantly as a 100 kilodalton (kDa) complex with PAI-1, as verified by immunoprecipitation. During infusions, t-PA circulated not only as free t-PA (55 kDa) but also in complexes with PAI-1 (100 kDa), alpha 2-antiplasmin (110 kDa), and C1-esterase inhibitor (170 kDa). After termination of infusions, levels of free t-PA declined, while inhibitor complexes remained prominent. Free PAI-1 activity, assayed spectrophotometrically, was markedly elevated in the 24 hr interval after infusion of t-PA in 47% of patients with infarction. The specific activity of t-PA during infusions was 0.4 IU/ng or greater. However, during the 3 hr interval after infusions in patients, specific activity declined in association with prominence of t-PA complexes, predominantly with PAI-1. Infusions of t-PA in normal rabbits did not result in reactive increases in PAI-1 activity or in the t-PA-PAI-1 complex. After infusions, t-PA was associated predominantly with alpha 2-antiplasmin and C1-esterase inhibitor rather than PAI-1. t-PA inhibitor complexes were seen despite immediate acidification of whole blood, indicating that they were present in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Circulation. 1988 Mar;77(3):660-9. doi: 10.1161/01.cir.77.3.660.
2
Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Circulation. 1989 Jun;79(6):1204-13. doi: 10.1161/01.cir.79.6.1204.
3
Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.组织型纤溶酶原激活物与纤溶酶原激活物抑制剂-1、α2-巨球蛋白及C1抑制物的复合物形成:电击或复杂分娩后去纤维蛋白和纤溶状态患者的研究
Blood. 1990 Feb 1;75(3):671-6.
4
Changes in various parameters of fibrinolysis in persons infused with tissue plasminogen activator: special reference to plasminogen activator inhibitor.
Thromb Res Suppl. 1988;8:23-33. doi: 10.1016/0049-3848(88)90151-x.
5
Alterations in the fibrinolytic system components during acute myocardial infarction.急性心肌梗死期间纤溶系统成分的改变。
Acta Cardiol. 2000 Aug;55(4):247-53. doi: 10.2143/AC.55.4.2005747.
6
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.
7
Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.人血浆中纤溶酶原激活物抑制剂-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的分子形式
Thromb Res. 1991 May 15;62(4):275-85. doi: 10.1016/0049-3848(91)90148-p.
8
Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.梗阻性黄疸中纤维蛋白溶解功能受损——来自临床和实验研究的证据。
Thromb Haemost. 1988 Aug 30;60(1):25-9.
9
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.经尿道前列腺切除术患者血液纤溶与术中或术后即刻失血之间缺乏相关性。
Br J Urol. 1997 Jul;80(1):105-10. doi: 10.1046/j.1464-410x.1997.00251.x.
10
Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.由于1型纤溶酶原激活物抑制剂功能活性降低导致的出血素质
J Clin Invest. 1989 May;83(5):1747-52. doi: 10.1172/JCI114076.

引用本文的文献

1
Lifetime Evaluation of Left Ventricular Structure and Function in Male C57BL/6J Mice after Gamma and Space-Type Radiation Exposure.雄性 C57BL/6J 小鼠γ和空间辐射暴露后左心室结构和功能的终生评估。
Int J Mol Sci. 2023 Mar 13;24(6):5451. doi: 10.3390/ijms24065451.
2
Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.纤溶酶原激活物抑制剂-1与心血管事件之间的关联:一项系统评价和荟萃分析。
Thromb J. 2018 Jun 5;16:12. doi: 10.1186/s12959-018-0166-4. eCollection 2018.
3
Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.
重编程的链激酶具有纤维蛋白靶向性,溶解血栓的效力比组织型纤溶酶原激活剂更强。
J Thromb Haemost. 2009 Aug;7(8):1321-8. doi: 10.1111/j.1538-7836.2009.03491.x. Epub 2009 Jun 30.
4
Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension.氯沙坦和赖诺普利对轻中度高血压患者纤溶系统的影响。
Clin Drug Investig. 2003;23(11):717-24. doi: 10.2165/00044011-200323110-00004.
5
Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.替奈普酶在急性心肌梗死溶栓治疗中的药代动力学和药效学
Clin Pharmacokinet. 2002;41(15):1229-45. doi: 10.2165/00003088-200241150-00001.
6
Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.凝血酶:结构、生物化学、检测及临床医学中的地位
J Thromb Thrombolysis. 1998 Jul;5(3):215-229. doi: 10.1023/A:1008843925851.
7
Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis.提高溶栓后冠状动脉再灌注的疗效和稳定性:探索凝血酶假说。
J Thromb Thrombolysis. 1995;1(2):133-144. doi: 10.1007/BF01062570.
8
Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.纤溶酶原激活物抑制剂:糖尿病患者心肌梗死的一个危险因素。
Br Heart J. 1993 Mar;69(3):228-32. doi: 10.1136/hrt.69.3.228.
9
Circadian variation in fibrinolytic activity in patients with variant angina.变异型心绞痛患者纤溶活性的昼夜变化
Br Heart J. 1994 Feb;71(2):156-61. doi: 10.1136/hrt.71.2.156.
10
Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.抗血小板药物作为组织纤溶酶原激活剂辅助药物在犬闭塞性冠状动脉血栓形成模型中的比较效果。
Br J Pharmacol. 1994 May;112(1):272-6. doi: 10.1111/j.1476-5381.1994.tb13063.x.